Vallon Pharmaceuticals, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. 6.15%54.020.9%$2353.35m
JNJJohnson & Johnson -0.62%159.250.7%$1167.23m
MRKMerck & Co., Inc. -3.83%79.130.7%$1134.44m
LLYEli Lilly & Co. -0.57%260.501.1%$694.38m
BMYBristol-Myers Squibb Co. -0.53%56.511.0%$694.21m
ABBVAbbVie, Inc. -1.80%116.531.9%$669.66m
AZNAstraZeneca Plc 0.43%56.581.0%$278.35m
GSKGlaxoSmithKline Plc -1.42%41.010.2%$185.81m
NVSNovartis AG -1.44%80.730.2%$180.89m
BFRIBiofrontera, Inc. 51.34%7.900.0%$139.46m
VTRSViatris, Inc. -2.30%12.750.0%$132.99m
RGENRepligen Corp. 5.21%286.016.7%$112.80m
RPRXRoyalty Pharma Plc -0.45%41.890.1%$106.76m
DRNADicerna Pharmaceuticals, Inc. -0.03%37.990.3%$106.72m
NVONovo Nordisk A/S -0.76%108.210.1%$96.98m

Company Profile

Vallon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of proprietary biopharmaceutical products. The firm's primary product is Abuse-Deterrent Amphetamine Immediate and its product pipeline includes ADAIR, ADMIR, ADHD, and Narcolepsy. The company was founded by David C. Baker on January 11, 2018 and is headquartered in Philadelphia, PA.